Post-quantum cryptographic techniques for message transformation across network stacks can secure the transmission of sensitive transcriptomic data in Multiple Sclerosis research, ensuring privacy during cross-institutional collaborations.
Adversarial Debate Score
60% survival rate under critique
Model Critiques
Supporting Research Papers
- A Physically-Informed Subgraph Isomorphism Approach to Molecular Docking Using Quantum Annealers
Molecular docking is a crucial step in the development of new drugs as it guides the positioning of a small molecule (ligand) within the pocket of a target protein. In the literature, a feasibility st...
- Resource-efficient Quantum Algorithms for Selected Hamiltonian Subspace Diagonalization
Quantum algorithms for selecting a subspace of Hamiltonians to diagonalize have emerged as a promising alternative to variational algorithms in the NISQ era. So far, such algorithms, which include the...
- Onset of Ergodicity Across Scales on a Digital Quantum Processor
Understanding how isolated quantum many-body systems thermalize remains a central question in modern physics. We study the onset of ergodicity in a two-dimensional disordered Heisenberg Floquet model ...
- Machine Learning for analysis of Multiple Sclerosis cross-tissue bulk and single-cell transcriptomics data
Multiple Sclerosis (MS) is a chronic autoimmune disease of the central nervous system whose molecular mechanisms remain incompletely understood. In this study, we developed an end-to-end machine learn...
- Universal Persistent Brownian Motions in Confluent Tissues
Biological tissues are active materials whose non-equilibrium dynamics emerge from distinct cellular force-generating mechanisms. Using a two-dimensional active foam model, we compare the effects of t...
Formal Verification
Z3 checks whether the hypothesis is internally consistent, not whether it is empirically true.
This discovery has a Claude-generated validation package with a full experimental design.
Precise Hypothesis
Post-quantum cryptographic (PQC) algorithms—specifically CRYSTALS-Kyber (key encapsulation) and CRYSTALS-Dilithium (digital signatures), as standardized by NIST in 2024—when implemented as a message transformation layer across TCP/IP and application-layer network stacks, will maintain end-to-end confidentiality and integrity of RNA-sequencing transcriptomic datasets (≥10,000 genes, ≥50 patient samples) transmitted between ≥2 geographically distinct MS research institutions, with: (a) encryption overhead <15% of baseline TLS 1.3 throughput, (b) zero plaintext leakage under simulated quantum adversary attacks (Grover/Shor algorithm emulation), and (c) full compliance with HIPAA/GDPR data minimization requirements, compared to classical RSA-2048/ECC-256 baselines under equivalent network conditions.
- PERFORMANCE DISPROOF: Measured encryption/decryption throughput overhead exceeds 25% compared to TLS 1.3 baseline on identical hardware for datasets ≥1 GB, making PQC operationally impractical for routine cross-institutional transfers.
- SECURITY DISPROOF: Any demonstrated plaintext recovery of ≥1 bit of transcriptomic data under simulated quantum attack (using quantum circuit simulators up to 40 qubits) or classical side-channel attack within the experimental environment.
- INTEGRITY DISPROOF: Dilithium signature verification failure rate >0.01% on transmitted datasets, indicating unreliable authentication.
- COMPLIANCE DISPROOF: Independent HIPAA/GDPR audit identifies ≥1 category-A violation (e.g., metadata leakage of patient identifiers through packet timing analysis) attributable to the PQC implementation rather than pre-existing infrastructure.
- SCALABILITY DISPROOF: System fails to maintain <500 ms key exchange latency when ≥10 simultaneous institutional connections are established (simulating multi-site MS consortium).
- INTEROPERABILITY DISPROOF: PQC layer causes >5% packet loss or requires protocol downgrade to classical cryptography in >20% of tested network configurations.
- CRYPTOGRAPHIC ASSUMPTION DISPROOF: Publication of a peer-reviewed polynomial-time algorithm solving LWE with security parameter n≥256 would invalidate the foundational assumption regardless of experimental results.
Experimental Protocol
PHASE 1 — Baseline Characterization (Days 1–15): Deploy classical TLS 1.3 (RSA-2048, ECDH-P256) between two emulated institutional nodes. Measure throughput, latency, CPU utilization, and memory consumption for transcriptomic dataset transfers of sizes: 100 MB, 1 GB, 10 GB, 50 GB. Record 30 independent trials per size.
PHASE 2 — PQC Implementation (Days 16–35): Implement CRYSTALS-Kyber-768/1024 + Dilithium3 using Open Quantum Safe (liboqs) library integrated into OpenSSL 3.x fork. Deploy identical network topology. Repeat all Phase 1 measurements under identical conditions.
PHASE 3 — Security Validation (Days 36–50): Conduct adversarial testing: (a) passive eavesdropping with full packet capture, (b) man-in-the-middle with certificate substitution, (c) replay attacks, (d) quantum circuit simulation of Grover's algorithm on 128-bit symmetric keys using Qiskit (up to 30-qubit simulation), (e) timing side-channel analysis using 10,000 repeated handshakes.
PHASE 4 — Compliance Audit (Days 51–60): Independent review of packet metadata, key management logs, and audit trails against HIPAA Security Rule (45 CFR §164.312) and GDPR Article 32 technical measures checklist.
PHASE 5 — Multi-Institutional Simulation (Days 61–75): Emulate 5-node MS research consortium (using GNS3 or AWS VPC peering) with simultaneous transfers. Measure aggregate throughput, key exchange success rate, and error rates.
- MS Transcriptomic Dataset: GTEx MS-relevant tissue RNA-seq data (dbGaP accession phs000424) — 200+ samples, 56,000 genes; or MS4MS consortium synthetic dataset (GDPR-compliant synthetic generation via SDV library if real data access delayed).
- Synthetic Patient Metadata: 500 synthetic patient records with realistic MS clinical covariates (EDSS scores, treatment history) generated via Synthea v3.0 for HIPAA compliance testing.
- Network Traffic Baseline: CAIDA anonymized packet traces for realistic WAN noise injection.
- Quantum Circuit Benchmarks: IBM Quantum Experience open benchmark circuits for Grover's algorithm validation (publicly available).
- PQC Reference Implementations: NIST PQC Round 3 submission packages (public domain); liboqs v0.9.0 source code (Apache 2.0).
- Cryptographic Test Vectors: NIST ACVTS (Automated Cryptographic Validation Testing System) test vectors for Kyber and Dilithium.
- Regulatory Checklist: HHS HIPAA Security Rule audit protocol (public); ENISA GDPR technical guidelines (public).
- Throughput overhead: PQC overhead ≤15% vs TLS 1.3 baseline for all file sizes ≥1 GB (primary criterion, p<0.05, N=30).
- Latency: Kyber768 handshake latency ≤200 ms at 99th percentile for single connections; ≤500 ms under 10 simultaneous connections.
- Security: Zero plaintext bits recovered in passive eavesdropping test; zero successful MITM attacks; TVLA |t| < 4.5 for timing analysis.
- Integrity: Dilithium3 signature verification success rate ≥99.99% across all transferred files.
- Quantum resistance: Grover circuit simulation confirms ≥128-bit post-quantum security level (requires >4,000 logical qubits for full attack).
- Compliance: ≥95% pass rate on HIPAA Security Rule controls; zero Category-A violations; GDPR Article 32 technical measures fully documented.
- Interoperability: <1% packet loss attributable to PQC layer; zero protocol downgrade events in 5-node simulation.
- NIST validation: 100% pass rate on ACVTS test vectors for Kyber768 and Dilithium3.
- Throughput overhead >25% for any dataset size ≥1 GB (hard stop — operationally impractical).
- Any plaintext recovery from encrypted transcriptomic data in eavesdropping tests.
- Any successful MITM attack that bypasses PQC authentication.
- TVLA |t| ≥ 4.5 indicating exploitable timing side-channel.
- Dilithium3 verification failure rate >0.01%.
- <90% pass rate on HIPAA controls or any Category-A violation.
- Key exchange latency >1,000 ms at 99th percentile under single-connection conditions.
-
5% packet loss attributable to PQC implementation.
- ACVTS test vector failure rate >0% (any cryptographic implementation error is disqualifying).
- System crash or memory exhaustion during 50 GB file transfer on specified hardware.
100
GPU hours
30d
Time to result
$1,000
Min cost
$10,000
Full cost
ROI Projection
- MARKET SIZE: Global healthcare cybersecurity market projected at $35.3B by 2028 (CAGR 19.1%); PQC-specific healthcare segment estimated at $2.1B by 2030.
- PRODUCT OPPORTUNITY: PQC-secured bioinformatics data transfer middleware (SaaS) — addressable market of 2,000+ MS research institutions globally at $50K–$200K/year licensing = $100M–$400M TAM.
- STANDARDS INFLUENCE: Validated protocol could become basis for NIH, EMA, or ISO standard for quantum-secure biomedical data sharing, providing first-mover advantage worth $500M+ in government contracts.
- INSURANCE VALUE: Cyber insurance premiums for research institutions average $2M–$5M/year; PQC certification could reduce premiums by 15–30% ($300K–$1.5M/year per institution).
- PHARMA PARTNERSHIP: MS drug developers (Biogen, Novartis, Roche) spend $500M–$2B/year on real-world evidence data acquisition; secure cross-institutional sharing infrastructure is a critical bottleneck worth $50M–$500M in partnership value.
- OPEN SOURCE IMPACT: If released as open-source reference implementation, could be adopted by 500+ biomedical research consortia globally, generating $10M–$50M in indirect economic value through research acceleration.
TIME_TO_RESULT_DAYS: 90
🔓 If proven, this unlocks
Proving this hypothesis is a prerequisite for the following downstream discoveries and applications:
- 1FEDERATED-LEARNING-PQC-MS-GENOMICS
- 2PQC-MULTIOMICS-CONSORTIUM-PROTOCOL
- 3QUANTUM-SECURE-BIOBANK-INFRASTRUCTURE
- 4PQC-CLINICAL-TRIAL-DATA-SHARING
- 5CROSS-BORDER-GDPR-PQC-COMPLIANCE-FRAMEWORK
- 6REAL-TIME-PQC-SCRNA-SEQ-STREAMING
Prerequisites
These must be validated before this hypothesis can be confirmed:
- PQC-NIST-STD-2024-KYBER
- LIBOQS-OPENSSL-INTEGRATION-v0.9
- MS-TRANSCRIPTOMIC-DBGAP-ACCESS
- HIPAA-AUDIT-FRAMEWORK-v2023
- SYNTHETIC-PATIENT-DATA-GENERATION
Implementation Sketch
# PQC Transcriptomic Data Transfer System — Architecture Outline ## COMPONENT 1: PQC-TLS Wrapper (Python/C) class PQCTransferAgent: def __init__(self, mode='kyber768_dilithium3'): self.kem = liboqs.KeyEncapsulation('Kyber768') self.sig = liboqs.Signature('Dilithium3') self.hybrid_mode = True # X25519 + Kyber768 hybrid def establish_session(self, peer_endpoint): # Step 1: Classical X25519 key exchange (backward compat) classical_shared = x25519_exchange(peer_endpoint) # Step 2: Kyber768 KEM encapsulation public_key, secret_key = self.kem.generate_keypair() ciphertext, kyber_shared = self.kem.encap_secret(peer_public_key) # Step 3: Hybrid key derivation (HKDF-SHA3-256) session_key = HKDF( input_key = classical_shared || kyber_shared, hash = SHA3_256, info = b'MS-transcriptomic-transfer-v1' ) return session_key def sign_and_send(self, data_chunk, session_key): # AES-256-GCM encryption with PQC-derived key ciphertext, tag = AES256GCM.encrypt(data_chunk, session_key) # Dilithium3 signature over ciphertext signature = self.sig.sign(ciphertext) # Packet: [length_header | ciphertext | tag | signature] packet = pack_frame(ciphertext, tag, signature) return packet def receive_and_verify(self, packet, session_key): ciphertext, tag, signature = unpack_frame(packet) # Verify Dilithium3 signature BEFORE decryption (fail-fast) if not self.sig.verify(ciphertext, signature, peer_public_key): raise SecurityException("Signature verification failed") # Decrypt only after signature verified plaintext = AES256GCM.decrypt(ciphertext, tag, session_key) return plaintext ## COMPONENT 2: Transcriptomic Data Pipeline Integration class MSDataTransferPipeline: def __init__(self, source_institution, dest_institution): self.pqc_agent = PQCTransferAgent() self.chunker = AdaptiveChunker(chunk_size_mb=64) # Optimize for MTU self.audit_log = HIPAACompliantLogger() def transfer_rnaseq_dataset(self, hdf5_file_path, metadata): # Strip PII from metadata before transfer sanitized_metadata = PIIStripper.process(metadata) # Establish PQC session session = self.pqc_agent.establish_session(dest_institution.endpoint) # Chunk and transfer for chunk in self.chunker.iterate(hdf5_file_path): encrypted_packet = self.pqc_agent.sign_and_send(chunk, session.key) self.network_send(encrypted_packet) self.audit_log.record_transfer_event( chunk_hash=SHA3_256(chunk), timestamp=UTC_now(), institution_pair=anonymized_pair_id ) # Transfer completion verification self.verify_integrity(session, expected_hash=SHA3_256(full_file)) ## COMPONENT 3: Benchmarking Harness class BenchmarkSuite: test_sizes = [100*MB, 1*GB, 10*GB, 50*GB] n_trials = 30 def run_comparison(self): results = {} for size in self.test_sizes: results[size] = { 'tls13_rsa': self.benchmark_classical(size), 'pqc_kyber768': self.benchmark_pqc(size), 'overhead_pct': compute_overhead(...) } return StatisticalReport(results, test='welch_t', alpha=0.05) ## COMPONENT 4: Security Test Suite class SecurityTestSuite: def test_passive_eavesdrop(self): ... # pcap analysis def test_mitm_resistance(self): ... # mitmproxy integration def test_timing_sidechannel(self): ... # TVLA methodology def test_quantum_grover(self): ... # Qiskit circuit simulation def test_replay_attack(self): ... # Nonce/sequence validation ## DEPLOYMENT ARCHITECTURE: # Institution A ←→ [PQC Gateway A] ←→ [WAN/Internet] ←→ [PQC Gateway B] ←→ Institution B # ↓ ↓ # [HSM Key Store] [HSM Key Store] # [Audit Logger] [Audit Logger] # ↓ ↓ # [SIEM System] ←————— Compliance Dashboard ————→ [SIEM System]
CHECKPOINT 1 (Day 7): NIST ACVTS test vector validation. ABORT if Kyber768 or Dilithium3 pass rate <100%. Indicates implementation error requiring library replacement or patching before any security claims are valid.
CHECKPOINT 2 (Day 20): Baseline TLS 1.3 benchmarking complete. ABORT if baseline throughput <800 Mbps on 10 GbE hardware (indicates hardware/network misconfiguration that would confound all subsequent comparisons).
CHECKPOINT 3 (Day 35): Initial PQC throughput results. ABORT if overhead >40% for 1 GB files (indicates fundamental performance problem unlikely to be resolved by optimization; hypothesis fails on practicality grounds).
CHECKPOINT 4 (Day 42): Passive eavesdropping test. ABORT IMMEDIATELY if any plaintext transcriptomic data recovered from PQC-encrypted stream (critical security failure; do not proceed to multi-institutional simulation with real data).
CHECKPOINT 5 (Day 50): Timing side-channel analysis. ABORT if TVLA |t| ≥ 4.5 on primary key operations (exploitable side-channel; requires library-level fix before deployment recommendation).
CHECKPOINT 6 (Day 58): HIPAA compliance pre-audit. ABORT if >3 Category-A violations identified (indicates architectural redesign needed; proceeding would produce non-compliant system).
CHECKPOINT 7 (Day 70): Multi-node simulation stability. ABORT if >10% connection failure rate or >15% packet loss in 5-node topology (indicates scalability failure incompatible with real consortium deployment).
CHECKPOINT 8 (Day 80): Integrated system test with synthetic MS data. ABORT if end-to-end transfer of 10 GB synthetic transcriptomic dataset fails to complete within 3× the TLS 1.3 baseline time (combined performance + reliability failure threshold).
📡 New evidence since EVP generation
Discoveries published after this EVP was written that relate to its hypothesis or downstream unlocks.
- Related
- Related